CNC:NYE-Centene Corporation (USD)

EQUITY | Healthcare Plans | New York Stock Exchange

Last Closing

USD 60.25

Change

+0.67 (+1.12)%

Market Cap

USD 9.48B

Volume

4.15M

Analyst Target

USD 85.36
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Centene Corp is a diversified multi-national healthcare enterprise. The Company provides programs and services to government sponsored healthcare programs, focusing on under-insured and uninsured individuals.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-23 )

Largest Industry Peers for Healthcare Plans

Symbol Name Price(Change) Market Cap
UNH UnitedHealth Group Incorporate..

+6.21 (+1.24%)

USD 460.26B
ELV Elevance Health Inc

+4.93 (+1.35%)

USD 88.46B
MOH Molina Healthcare Inc

-0.23 (-0.08%)

USD 16.86B
OSCR Oscar Health Inc

-0.49 (-3.48%)

USD 4.09B
NEUE NeueHealth Inc

+0.49 (+12.83%)

USD 0.05B
CI Cigna Corp

+4.71 (+1.70%)

N/A
CVS CVS Health Corp

-0.22 (-0.50%)

N/A
HUM Humana Inc

+8.64 (+3.50%)

N/A

ETFs Containing CNC

MVPA Advisor Managed Portfolio.. 4.70 % 0.00 %

-0.15 (-0.43%)

USD 0.07B
AVDR 2.70 % 0.00 %

N/A

N/A
DXSD:F 2.30 % 0.00 %

N/A

N/A
DXSD:XETRA 2.30 % 0.00 %

N/A

N/A
IHF iShares U.S. Healthcare P.. 0.00 % 0.43 %

+0.34 (+-0.43%)

N/A
ONEV SPDR® Russell 1000 Low V.. 0.00 % 0.20 %

-0.68 (-0.43%)

N/A
JNKS:LSE SSgA SPDR ETFs Europe I p.. 0.00 % 0.00 %

+0.10 (+-0.43%)

USD 0.18B
SYBK:F SSgA SPDR ETFs Europe I p.. 0.00 % 0.00 %

-0.01 (-0.43%)

USD 0.14B
SYBK:XETRA SPDR Barclays 0-5 Year US.. 0.00 % 0.00 %

-0.02 (-0.43%)

USD 0.13B
GBLO 0.00 % 0.00 %

N/A

N/A
NVQ 0.00 % 0.00 %

N/A

N/A
FSBD Fidelity Sustainable Core.. 0.00 % 0.00 %

-0.21 (-0.43%)

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Healthcare Plans) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -18.81% 50% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.81% 50% F 12% F
Trailing 12 Months  
Capital Gain -17.85% 50% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.85% 50% F 12% F
Trailing 5 Years  
Capital Gain -4.71% 50% F 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.71% 50% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain 1.92% 50% F 40% F
Dividend Return 1.92% 25% F 31% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.08% 38% F 42% F
Risk Adjusted Return 7.36% 25% F 25% F
Market Capitalization 9.48B 67% D+ 93% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Healthcare Plans) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.70 80% 74%
Price/Book Ratio 1.10 100% 66%
Price / Cash Flow Ratio 3.74 67% 65%
Price/Free Cash Flow Ratio 5.11 75% 70%
Management Effectiveness  
Return on Equity 11.56% 50% 67%
Return on Invested Capital 4.74% 50% 44%
Return on Assets 3.51% 50% 63%
Debt to Equity Ratio 68.54% 17% 50%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.